A clinical study assessing STP369 for head and neck cancer and bladder cancer
Latest Information Update: 25 May 2022
At a glance
- Drugs STP 369 (Primary)
- Indications Bladder cancer; Head and neck cancer
- Focus Adverse reactions
- Sponsors Sirnaomics
Most Recent Events
- 25 May 2022 New trial record
- 20 May 2022 According to Sirnaomics media release, the Company intends to file IND to initiate this clinical study in 2023